Natalie Reizine

11PUBLICATIONS
75CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer geneticsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jun 09, 2026
The evolving landscape and clinical utility of circulating tumor DNA across the spectrum of urothelial carcinoma: A systematic review and framework for clinical integration.

|Aug 12, 2025
SOX2 utilizes FOXA1 as a heteromeric transcriptional partner to drive proliferation in therapy-resistant prostate cancer.

John T Phoenix, Audris Budreika, Devin A Schmeck

|Jan 02, 2025
Structurally Oriented Classification of FOXA1 Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes.

Justin Hwang, Pornlada Likasitwatanakul, Sachin Kumar Deshmukh

|Dec 11, 2024
Comparative Analysis of Generative Pre-Trained Transformer Models in Oncogene-Driven Non-Small Cell Lung Cancer: Introducing the Generative Artificial Intelligence Performance Score.

Zacharie Hamilton, Aseem Aseem, Zhengjia Chen

|Feb 02, 2024
ERBB3 Overexpression is Enriched in Diverse Patient Populations with Castration-sensitive Prostate Cancer and is Associated with a Unique AR Activity Signature.

Jordan E Vellky, Brenna J Kirkpatrick, Lisa C Gutgesell

|Mar 30, 2023
Utilization of Next-Generation Sequencing in Conjunction With Immunohistochemistry to Predict Exceptional Response to Combination Immune Checkpoint Therapy in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer.

Natalie Reizine, Samantha Socco, Eric Weng

Pageof 2

Frequent Collaborators

2 joint publications

Peter H O'Donnell

2 joint publications

Jordan E Vellky

2 joint publications

Justin Hwang

2 joint publications

Donald J Vander Griend